» Articles » PMID: 33445508

Enhanced Expression of in B Cells of CLL Improves the Anti-Tumor Cytotoxic T Cell Response

Abstract

The clinical progression of B cell chronic lymphocytic leukemia (CLL) is associated with immune cell dysfunction and a strong decrease of (), promoting the death of CLL cells. Here we investigated whether the reduction of impairs the immune response in CLL. We demonstrate that activated CD4+ T cells increase expression in CLL through CD40-CD40L signaling, which enhances the maturation and activity of cytotoxic T cells and, consequently, the apoptotic response of CLL cells. The cytotoxic response is facilitated by a depletion of the anti-inflammatory cytokine interleukin 10, targeted by . In vivo experiments in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice confirmed that promotes the apoptotic death of CLL cells only when functional T cells are restored. Overall, our findings suggest that the reinstatement of in CLL cells could be an exploitable adjuvant therapeutic option for the treatment of CLL.

Citing Articles

The modulation of immune cell death in connection to microRNAs and natural products.

Chuang Y, Yen C, Tang J, Chang F, Tsai Y, Wu K Front Immunol. 2025; 15:1425602.

PMID: 39759512 PMC: 11695430. DOI: 10.3389/fimmu.2024.1425602.


Dysregulated MicroRNAs in Chronic Lymphocytic Leukemia.

Mesaros O, Veres S, Onciul M, Matei E, Jimbu L, Neaga A Cureus. 2024; 16(9):e68770.

PMID: 39376808 PMC: 11456419. DOI: 10.7759/cureus.68770.


Exploring the Immunomodulatory Potential of Pancreatic Cancer-Derived Extracellular Vesicles through Proteomic and Functional Analyses.

Piro A, Cufaro M, Lanuti P, Brocco D, De Lellis L, Florio R Cancers (Basel). 2024; 16(10).

PMID: 38791876 PMC: 11120044. DOI: 10.3390/cancers16101795.


CTLs heterogeneity and plasticity: implications for cancer immunotherapy.

Peng S, Lin A, Jiang A, Zhang C, Zhang J, Cheng Q Mol Cancer. 2024; 23(1):58.

PMID: 38515134 PMC: 10956324. DOI: 10.1186/s12943-024-01972-6.


Identification and clinical value of a new ceRNA axis (TIMP3/hsa-miR-181b-5p/PAX8-AS1) in thyroid cancer.

Liang J, Deng Y, Zhang Y, Wu B, Zhou J Health Sci Rep. 2024; 7(2):e1859.

PMID: 38410497 PMC: 10895078. DOI: 10.1002/hsr2.1859.


References
1.
Malavasi F, Deaglio S, Funaro A, Ferrero E, Horenstein A, Ortolan E . Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008; 88(3):841-86. DOI: 10.1152/physrev.00035.2007. View

2.
Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B . Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017; 17(5):286-301. DOI: 10.1038/nrc.2017.17. View

3.
Peter M, Hadji A, Murmann A, Brockway S, Putzbach W, Pattanayak A . The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 2015; 22(5):885-6. PMC: 4392084. DOI: 10.1038/cdd.2015.25. View

4.
Yang X, Boehm J, Yang X, Salehi-Ashtiani K, Hao T, Shen Y . A public genome-scale lentiviral expression library of human ORFs. Nat Methods. 2011; 8(8):659-61. PMC: 3234135. DOI: 10.1038/nmeth.1638. View

5.
Chu P, Wierda W, Kipps T . CD40 activation does not protect chronic lymphocytic leukemia B cells from apoptosis induced by cytotoxic T lymphocytes. Blood. 2000; 95(12):3853-8. View